Clinical Trials
2 trialsNCT03916094 2022-05-05
Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
Shanghai Henlius Biotech
Phase 1 Completed
NCT02593708 2017-11-17
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
University of California, San Francisco
Phase 1 Terminated